DK1286964T3 - Heterocykliske inhibitorer glycogensynthasekinase GSK-3 - Google Patents

Heterocykliske inhibitorer glycogensynthasekinase GSK-3

Info

Publication number: DK1286964T3
Authority: DK; Denmark
Prior art keywords: glycogen synthase; synthase kinase; disease; heterocyclic inhibitors; gsk
Prior art date: 2000-05-11

Application number

DK01928117T

Other languages

English (en)

Inventor

Martin Maria Concepcion Perez

Jurado Francisco Wandosell

Gil Ana Martinez

Morera Ana Castro

Mercedes Alonso Cascon

Isabel Dorronsoro Diaz

Munoz Francisco Jose Moreno

Original Assignee

Univ Madrid Autonoma

Consejo Superior Investigacion

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-11

Filing date

2001-05-11

Publication date

2007-10-01

2000-05-11 Priority claimed from ES200001185A external-priority patent/ES2166328B1/es

2001-05-11 Application filed by Univ Madrid Autonoma, Consejo Superior Investigacion filed Critical Univ Madrid Autonoma

2007-10-01 Application granted granted Critical

2007-10-01 Publication of DK1286964T3 publication Critical patent/DK1286964T3/da

Links

102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 title abstract 2
125000000623 heterocyclic group Chemical group 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010003210 Arteriosclerosis Diseases 0.000 abstract 1
108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
206010054949 Metaplasia Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000003463 hyperproliferative effect Effects 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000015689 metaplastic ossification Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/13—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/385—Saturated compounds containing a keto group being part of a ring
- C07C49/395—Saturated compounds containing a keto group being part of a ring of a five-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/597—Unsaturated compounds containing a keto groups being part of a ring of a five-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Hematology (AREA)
Obesity (AREA)
Oncology (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK01928117T 2000-05-11 2001-05-11 Heterocykliske inhibitorer glycogensynthasekinase GSK-3 DK1286964T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
ES200001185A ES2166328B1 (es)	2000-05-11	2000-05-11	Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
GB0030284A GB0030284D0 (en)	2000-05-11	2000-12-12	Enzyme inhibitors
PCT/GB2001/002100 WO2001085685A1 (en)	2000-05-11	2001-05-11	Heterocyclic inhibitors of glycogen synthase kinase gsk-3

Publications (1)

Publication Number	Publication Date
DK1286964T3 true DK1286964T3 (da)	2007-10-01

Family

ID=26156184

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01928117T DK1286964T3 (da)	2000-05-11	2001-05-11	Heterocykliske inhibitorer glycogensynthasekinase GSK-3

Country Status (19)

Country	Link
US (3)	US6872737B2 (da)
EP (1)	EP1286964B1 (da)
KR (1)	KR100812407B1 (da)
CN (1)	CN100358867C (da)
AT (1)	ATE366238T1 (da)
AU (1)	AU783615B2 (da)
BR (1)	BR0110734A (da)
CA (1)	CA2408747C (da)
CY (1)	CY1106826T1 (da)
CZ (1)	CZ296087B6 (da)
DE (1)	DE60129222T2 (da)
DK (1)	DK1286964T3 (da)
ES (1)	ES2288948T3 (da)
HU (1)	HUP0302002A3 (da)
IL (1)	IL152721A0 (da)
MX (1)	MXPA02011079A (da)
PL (1)	PL209780B1 (da)
RU (1)	RU2294931C2 (da)
WO (1)	WO2001085685A1 (da)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2408747C (en) *	2000-05-11	2011-04-05	Consejo Superior Investigaciones Cientificas	Heterocyclic inhibitors of glycogen synthase kinase gsk-3
WO2003018011A1 (en)	2001-08-24	2003-03-06	Wyeth Holdings Corporation	5-(substituted)-5-(substitutedsulfonyl or sulfanyl)thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
WO2003018554A1 (en)	2001-08-24	2003-03-06	Wyeth Holdings Corporation	3-substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
CN1741821B (zh) *	2002-10-29	2011-08-10	恩根尼公司	用于癌症治疗的组合物
GB0303319D0 (en)	2003-02-13	2003-03-19	Novartis Ag	Organic compounds
GB0327908D0 (en) *	2003-12-02	2004-01-07	Neuropharma Sa	GSK-3 inhibitors isolated from marine organisms
SE0303570L (sv) *	2003-12-03	2005-06-04	Microdrug Ag	Fukt-känslig medicinsk produkt
EP1574499A1 (en) *	2004-03-08	2005-09-14	DKFZ Deutsches Krebsforschungszentrum	Inhibitors of DNA methylation in tumor cells
EP1586318A1 (en) *	2004-04-05	2005-10-19	Neuropharma S.A.U.	Thiadiazolidinones as GSK-3 inhibitors
WO2006034207A2 (en) *	2004-09-17	2006-03-30	Vanderbilt University	Use of gsk3 inhibitors in combination with radiation therapies
WO2006045581A1 (en) *	2004-10-21	2006-05-04	Neuropharma, S.A.	The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
KR20070094963A (ko) *	2005-01-10	2007-09-27	아스트라제네카 아베	간 ｘ 수용체 조절제로서 이소티아졸-3(2ｈ)-온1,1-디옥사이드 유도체
SE0500058D0 (sv) *	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 5
WO2006073364A1 (en) *	2005-01-10	2006-07-13	Astrazeneca Ab	Derivatives of isothiazol-3 (2h)-thione 1,1-dioxides as liver x receptor modulators
SE0500056D0 (sv) *	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 4
SE0500055D0 (sv) *	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 3
DK1846406T5 (da)	2005-02-09	2011-10-31	Arqule Inc	Maleimidderivater, farmaceutiske sammensætninger og fremgangsmåder til behandling af cancer
ES2258406B1 (es) *	2005-02-10	2007-12-01	Neuropharma, S.A.	Uso de compuestos heterociclicos como agentes neurogenicos.
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja)	2005-08-26	2009-02-12	ブレインセルス，インコーポレイティド	ムスカリン性受容体調節による神経発生
US7985756B2 (en)	2005-10-21	2011-07-26	Braincells Inc.	Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
WO2007134077A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 ht receptor mediated neurogenesis
US8168667B2 (en)	2006-05-31	2012-05-01	Galapagos Nv	Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
CA2658263A1 (en)	2006-07-18	2008-01-24	University Of Rochester	Thiadiazolidinone derivatives
EP2068872A1 (en)	2006-09-08	2009-06-17	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
EP2089023A2 (en)	2006-11-02	2009-08-19	Aestus Therapeutics, Inc.	Methods of treating neuropathic pain with agonists of ppar-gamma
CN101801937A (zh)	2007-06-22	2010-08-11	艾科尔公司	喹唑啉酮化合物及其使用方法
JP5490688B2 (ja)	2007-06-22	2014-05-14	アークルインコーポレイテッド	癌の治療のためのインドリルピロリジン
CA2690799C (en)	2007-06-22	2015-06-16	Arqule, Inc.	Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
US9029408B2 (en)	2008-06-16	2015-05-12	Gtx, Inc.	Compounds for treatment of cancer
US9447049B2 (en)	2010-03-01	2016-09-20	University Of Tennessee Research Foundation	Compounds for treatment of cancer
DK2303021T3 (da) *	2008-06-16	2019-04-08	Univ Tennessee Res Found	Forbindelser til behandling af kræft
GB2463514C (en)	2008-09-11	2018-09-26	Galapagos Nv	Imidazolidine compounds and uses therefor
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CN101519372B (zh) *	2009-04-01	2011-07-20	深圳市盛捷生物技术有限公司	用作GSK3抑制剂的苯并[e]异吲哚-1,3-二酮化合物及其制备
ME02443B (me)	2009-07-08	2016-09-20	Baltic Bio Ab	Derivati 1,2,4-tiazolidin-3-ona i njihova upotreba u liječenju kancera
ITNA20090047A1 (it) *	2009-07-16	2011-01-17	Adele Bolognese	Agenti antitumorali con attività inibitoria di proteine di prenilazione, processo di preparazione e impieghi in campo medico
US8765920B2 (en)	2009-12-23	2014-07-01	The Scripps Research Institute	Tyrosine bioconjugation through aqueous Ene-like reactions
KR101939704B1 (ko)	2010-03-01	2019-01-17	지티엑스, 인코포레이티드	암 치료용 화합물
WO2011151359A1 (en)	2010-06-02	2011-12-08	Noscira, S.A.	Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
US11068954B2 (en)	2015-11-20	2021-07-20	Voicemonk Inc	System for virtual agents to help customers and businesses
NZ611169A (en)	2010-12-01	2014-05-30	Nissan Chemical Ind Ltd	Pyrazole compounds having therapeutic effect on multiple myeloma
US8865750B2 (en) *	2011-04-28	2014-10-21	The Regents Of The University Of Michigan	Small molecule inhibitors of RGS proteins
EP2527323A1 (en)	2011-05-24	2012-11-28	Noscira, S.A.	Urea carbonyl disulfide derivatives and their therapeutic uses
WO2013020024A2 (en) *	2011-08-03	2013-02-07	Karyopharm Therapeutics, Inc.	Maleimide compounds and methods of treatment
WO2013108026A1 (en)	2012-01-17	2013-07-25	Baltic Bio Ab	Thiadiazolone derivatives useful in the treatment of diabetes
WO2013124413A1 (en)	2012-02-24	2013-08-29	Noscira, S.A.	Thiadiazolidinediones as gsk-3 inhibitors
CN103992312A (zh) *	2013-02-18	2014-08-20	江苏欧威医药有限公司	1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和应用
EP2974726A4 (en) *	2013-03-14	2017-01-04	Tiacen Ltd	Agent for the prophylaxis and/or treatment of neoplastic diseases
RU2522449C1 (ru) *	2013-03-14	2014-07-10	Общество с ограниченной ответственностью "Лечебное питание"	Средство, обладающее антипролиферативным и антиметастатическим действием, для лечения опухолевых заболеваний
DK2970890T3 (da)	2013-03-14	2020-05-04	Brigham & Womens Hospital Inc	Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
WO2015017549A1 (en) *	2013-07-30	2015-02-05	University Of South Florida (A Florida Non-Profit Corporation)	Treating an atypical protein kinase c enzyme abnormality
US20170165230A1 (en)	2014-04-09	2017-06-15	Christopher Rudd	Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
WO2016037016A1 (en)	2014-09-03	2016-03-10	The Brigham And Women's Hospital, Inc.	Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
US9540462B2 (en)	2014-12-05	2017-01-10	Massachusetts Institute Of Technology	Catechol-rich polymers from N-substituted maleimides
MX376146B (es)	2015-03-17	2025-03-07	Regeneron Pharma	Reactivos de acilacion de aminoacidos y metodos para usar los mismos.
JP2019506153A (ja)	2016-01-08	2019-03-07	マサチューセッツインスティテュートオブテクノロジー	分化した腸内分泌細胞およびインスリン産生細胞の作製
US11260130B2 (en)	2016-03-02	2022-03-01	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en)	2016-03-02	2019-02-12	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en)	2016-03-02	2019-02-26	Frequency Therapeutics, Inc.	Thermoreversible compositions for administration of therapeutic agents
MX390321B (es)	2016-12-30	2025-03-20	Frequency Therapeutics Inc	Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
RU2761429C2 (ru) *	2018-06-13	2021-12-08	Общество с ограниченной ответственностью "Тиацен"	Средство, обладающее противоопухолевым действием, для лечения онкологических заболеваний
JP2021533788A (ja)	2018-08-17	2021-12-09	フリークエンシーセラピューティクスインコーポレイテッド	Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法
WO2020037326A1 (en)	2018-08-17	2020-02-20	Frequency Therapeutics, Inc.	Compositions and methods for generating hair cells by downregulating foxo
EP3920885A1 (en)	2019-02-08	2021-12-15	Frequency Therapeutics, Inc.	Valproic acid compounds and wnt agonists for treating ear disorders
CN110698380B (zh) *	2019-10-24	2021-01-15	华东理工大学	一种内酰胺衍生物及其制备方法与应用
US12150936B2 (en)	2021-02-11	2024-11-26	Venca Research, Inc.	Compositions and methods for treating arrhythmogenic cardiomyopathy
CA3219537A1 (en)	2021-05-21	2022-11-24	Michael Snape	Method of treating rna repeat mediated diseases with rna repeat binding compound
EP4094760A1 (en)	2021-05-24	2022-11-30	Consejo Superior De Investigaciones Científicas	Thiadiazolidinones for their use in the treatment of limb-girdle muscular dystrophy
CN115197167B (zh) *	2022-07-22	2023-07-28	中国药科大学	1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2863803A (en) *	1957-05-13	1958-12-09	Stauffer Chemical Co	Protecting materials against fungi by applying substituted dithiono and thiono-oxo-thiadiazolidines
US3301894A (en)	1964-11-16	1967-01-31	Olin Mathieson	S-[nu'-(chlorocarbonyl)-amino] isothiocarbamyl chlorides and their preparation
DE1670701A1 (de)	1966-05-23	1970-11-12	Bayer Ag	Verfahren zur Darstellung von Thiaimidazolidinen
US3900485A (en)	1967-02-10	1975-08-19	Velsicol Chemical Corp	New substituted 1,2,4-thiadiazolidine-3,5-diones
US3534057A (en)	1968-05-28	1970-10-13	Velsicol Chemical Corp	Halogenation process for the production of certain oxadiazolidines and thiadiazolidines
DE2109755A1 (de)	1971-03-02	1972-09-07	Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen	Substituierte Thiadiazolidindione
US4183816A (en) *	1978-11-01	1980-01-15	Olin Corporation	Use of 2,4-di(lower alkyl)-1,2,4-thiadiazolidin-3,5-diones as additives for functional fluids
JPS58216177A (ja)	1982-06-10	1983-12-15	Sumitomo Chem Co Ltd	フエニルチアジアゾリジンジオン誘導体、その製造法および該化合物を有効成分として含有する除草剤
DK0817627T3 (da) *	1993-12-23	2005-06-06	Lilly Co Eli	Inhibitorer af proteinkinase C
JP3714685B2 (ja) *	1994-05-18	2005-11-09	第一サントリーファーマ株式会社	ハイメニアルディシン及びその誘導体並びにそれらの合成中間体の製造法並びにその合成中間体
DE4420522A1 (de) *	1994-06-13	1995-12-14	Bayer Ag	Bakterizide Thiadiazolidinone
JP2002527419A (ja) *	1998-10-08	2002-08-27	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	Ｇｓｋ−３阻害物質としてのピロール−２，５−ジオン類
GB9828640D0 (en) *	1998-12-23	1999-02-17	Smithkline Beecham Plc	Novel method and compounds
GB9918180D0 (en) *	1999-08-02	1999-10-06	Smithkline Beecham Plc	Novel compositions
CA2408747C (en)	2000-05-11	2011-04-05	Consejo Superior Investigaciones Cientificas	Heterocyclic inhibitors of glycogen synthase kinase gsk-3
GB0012056D0 (en)	2000-05-18	2000-07-12	Consejo Superior Investigacion	Model for neurodegenerative disease
EP1586318A1 (en)	2004-04-05	2005-10-19	Neuropharma S.A.U.	Thiadiazolidinones as GSK-3 inhibitors

2001
- 2001-05-11 CA CA2408747A patent/CA2408747C/en not_active Expired - Lifetime
- 2001-05-11 RU RU2002133222/04A patent/RU2294931C2/ru not_active IP Right Cessation
- 2001-05-11 MX MXPA02011079A patent/MXPA02011079A/es active IP Right Grant
- 2001-05-11 BR BR0110734-8A patent/BR0110734A/pt not_active Application Discontinuation
- 2001-05-11 DE DE60129222T patent/DE60129222T2/de not_active Expired - Lifetime
- 2001-05-11 WO PCT/GB2001/002100 patent/WO2001085685A1/en not_active Ceased
- 2001-05-11 CZ CZ20023692A patent/CZ296087B6/cs not_active IP Right Cessation
- 2001-05-11 AT AT01928117T patent/ATE366238T1/de active
- 2001-05-11 DK DK01928117T patent/DK1286964T3/da active
- 2001-05-11 IL IL15272101A patent/IL152721A0/xx unknown
- 2001-05-11 KR KR1020027015132A patent/KR100812407B1/ko not_active Expired - Fee Related
- 2001-05-11 CN CNB01812738XA patent/CN100358867C/zh not_active Expired - Lifetime
- 2001-05-11 HU HU0302002A patent/HUP0302002A3/hu unknown
- 2001-05-11 PL PL359671A patent/PL209780B1/pl unknown
- 2001-05-11 AU AU54981/01A patent/AU783615B2/en not_active Ceased
- 2001-05-11 ES ES01928117T patent/ES2288948T3/es not_active Expired - Lifetime
- 2001-05-11 EP EP01928117A patent/EP1286964B1/en not_active Expired - Lifetime
2002
- 2002-11-08 US US10/290,569 patent/US6872737B2/en not_active Expired - Lifetime
2004
- 2004-08-12 US US10/917,175 patent/US7666885B2/en not_active Expired - Lifetime
2007
- 2007-04-20 US US11/788,755 patent/US7781463B2/en not_active Expired - Fee Related
- 2007-08-30 CY CY20071101111T patent/CY1106826T1/el unknown

Also Published As

Publication number	Publication date
CA2408747A1 (en)	2001-11-15
CZ296087B6 (cs)	2006-01-11
WO2001085685A1 (en)	2001-11-15
KR100812407B1 (ko)	2008-03-11
RU2294931C2 (ru)	2007-03-10
AU5498101A (en)	2001-11-20
CN100358867C (zh)	2008-01-02
US6872737B2 (en)	2005-03-29
DE60129222T2 (de)	2008-03-06
US7781463B2 (en)	2010-08-24
DE60129222D1 (de)	2007-08-16
KR20030025919A (ko)	2003-03-29
ATE366238T1 (de)	2007-07-15
CN1568310A (zh)	2005-01-19
EP1286964A1 (en)	2003-03-05
PL209780B1 (pl)	2011-10-31
HUP0302002A2 (hu)	2003-09-29
CZ20023692A3 (cs)	2003-06-18
PL359671A1 (en)	2004-09-06
HUP0302002A3 (en)	2007-02-28
US20080033012A1 (en)	2008-02-07
AU783615B2 (en)	2005-11-17
BR0110734A (pt)	2003-02-04
US20030195238A1 (en)	2003-10-16
CA2408747C (en)	2011-04-05
IL152721A0 (en)	2003-06-24
US7666885B2 (en)	2010-02-23
MXPA02011079A (es)	2004-08-19
ES2288948T3 (es)	2008-02-01
US20050014803A1 (en)	2005-01-20
CY1106826T1 (el)	2012-05-23
EP1286964B1 (en)	2007-07-04

Publication	Publication Date	Title
DE60129222D1 (de)	2007-08-16	Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
DE60215814D1 (de)	2006-12-14	Vinylphenyl-derivate als glk-aktivatoren
SE0102300D0 (sv)	2001-06-26	Compounds
IS2114B (is)	2006-06-15	Kínasólínafleiður til að meðhöndla æxli
BR0308243A (pt)	2005-01-11	Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
AP1588A (en)	2006-03-06	Pyrazole compounds useful as protein kinase inhibitors
MY146279A (en)	2012-07-31	Compounds affecting glucokinase
ATE334973T1 (de)	2006-08-15	Chinazolinverbindungen
DE60226729D1 (de)	2008-07-03	Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
IL173396A0 (en)	2006-06-11	Piperazine derivatives and their use as therapeutic agents
WO2006044497A3 (en)	2006-09-08	Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
ATE358668T1 (de)	2007-04-15	Drogen zur behandlung maligner tumoren
DE60215178D1 (de)	2006-11-16	Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
DE60229046D1 (de)	2008-11-06	Chinazolin derivate
UA83691C2 (ru)	2008-08-11	Применение замещенных 2-аминотетралинов для упреждающего лечения болезни паркинсона
IL159772A0 (en)	2004-06-20	Taxol enhancer compounds
DE60108626D1 (de)	2005-03-03	Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
PL1727817T3 (pl)	2011-03-31	Pochodne azabicyklooktan-3-onu i ich zastosowanie
WO2003080617A8 (en)	2003-11-13	Pyrazolopyrimidine derivatives
DE60114597D1 (de)	2005-12-08	Naphthamid-neurokinin antagonisten zur verwendung als medikamente